Affiliation:
1. Division of Epidemiology and Pharmacoepidemiology, Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan
Funder
Tokyo Women’s Medical University
Ayumi Pharmaceutical Co.
Bristol Myers Squib
Chugai Pharmaceutical Co., Ltd
Eisai Co., Ltd
Nippon Kayaku Co., Ltd
Taisho Toyama Pharmaceutical Co., Ltd
Takeda Pharmaceutical Co., Ltd
Mitsubishi Tanabe Pharma Co.
Teijin Pharma Ltd
Gilead Sciences, Inc.
Abbvie Japan Co., Ltd
Bristol-Myers Squibb K.K.
Ono Pharmaceutical Co., Ltd
Santen Pharmaceutical Co., Ltd
Teijin Pharma, Ltd
Pfizer Japan Inc.
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Reference62 articles.
1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017
2. The emerging safety profile of JAK inhibitors in rheumatic disease;Winthrop;Nat Rev Rheumatol,2017
3. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies;Wollenhaupt;J Rheumatol,2014
4. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years (Abstract 1647);Wollenhaupt;Arthritis Rheumatol,2017
5. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis (FRI0090);Kremer;Ann Rheum Dis,2017
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献